2017 Fiscal Year Final Research Report
Novel therapeutic approaches for renal failure via modulation of the gut microbiota
Project/Area Number |
15K19163
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Applied pharmacology
|
Research Institution | University of Toyama |
Principal Investigator |
Fukumori Shiro 富山大学, 大学院医学薬学研究部(薬学), 特命助教 (10714842)
|
Project Period (FY) |
2015-04-01 – 2018-03-31
|
Keywords | 腎不全 / 尿毒症毒素 / 腸内細菌叢 |
Outline of Final Research Achievements |
Indoxyl sulfate (IS) is a protein-bound uremic toxin generated by the gut microbiota. Recently, it has been reported that IS may be associated with the progression of kidney disease and also cardiovascular disease. The aim of this study was to examine the separate and combined effect of probiotics and prebiotics on renal failure using an adenine-induced renal failure mouse model. The monotherapy with the probiotic bacteria, Bifidobacterium longum and Lactobacillus casei (L.casei), and the prebiotic galacto-oligosaccharides (GOS) did not significantly reduce BUN and serum levels of IS. The combination therapy with L.casei and GOS reduce serum levels of IS in renal failure mice compared with the control group, though the difference was not statistically significant (p = 0.07). This study suggested that the combination therapy of probiotics and oligosaccharides could ameliorate the accumulation of uremic toxins by improving the gut microbiota.
|
Free Research Field |
臨床薬学
|